ArticleScientific reports2017
Schisandrin A inhibits dengue viral replication via upregulating antiviral interferon responses through STAT signaling pathway.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Schisandrin A ameliorates the diabetes-associated memory impairment by alleviating inflammation and ferroptosis.Acta biochimica et biophysica Sinica · 2025Article
- A comprehensive review of Schisandra chinensis lignans: pharmacokinetics, pharmacological mechanisms, and future prospects in disease prevention and treatment.Chinese medicine · 2025Review
- Assessing Traditional Chinese Medicines for Anti-Dengue Using a National Health Insurance Research Database and Bioassays.Food science & nutrition · 2025Article
- The Current Landscape of Bioactive Molecules against DENV: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2023Review
- Therapeutic Potential of Medicinal Plants against Dengue Infection: A Mechanistic Viewpoint.ACS omega · 2022Review
- Traditional Knowledge to Contemporary Medication in the Treatment of Infectious Disease Dengue: A Review.Frontiers in pharmacology · 2022Review
- Potential protective benefits of Schisandrin B against severe acute hepatitis in children during the COVID-19 pandemic based on a network pharmacology analysis.Frontiers in pharmacology · 2022Article
- INMI1 Zika Virus NS4B Antagonizes the Interferon Signaling by Suppressing STAT1 Phosphorylation.Viruses · 2021Article
- Article
- Medicinal plants: Treasure for antiviral drug discovery.Phytotherapy research : PTR · 2021Review
- Dibenzocyclooctadiene Lignans in Plant Parts and Fermented Beverages ofPlants (Basel, Switzerland) · 2021Article
- Regulation of Host Innate Immunity by Non-Coding RNAs During Dengue Virus Infection.Frontiers in cellular and infection microbiology · 2020Review
- Lignans and Their Derivatives from Plants as Antivirals.Molecules (Basel, Switzerland) · 2020Review
- Contemporary Strategies and Current Trends in Designing Antiviral Drugs against Dengue Fever via Targeting Host-Based Approaches.Microorganisms · 2019Review
- Genome-wide profiling of mRNA and lncRNA expression in dengue fever and dengue hemorrhagic fever.FEBS open bio · 2019Article
- Potential ofNutrients · 2019Review
- Avocado (Persea americana) fruit extract (2R,4R)-1,2,4-trihydroxyheptadec-16-yne inhibits dengue virus replication via upregulation of NF-κB-dependent induction of antiviral interferon responses.Scientific reports · 2019Article
- Dengue virus and the host innate immune response.Emerging microbes & infections · 2018Review
- ICR suckling mouse model of Zika virus infection for disease modeling and drug validation.PLoS neglected tropical diseases · 2018Article
- Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate.Journal of biomedical science · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue virus (DENV) infects 400 million people worldwide annually. Infection of more than one serotype of DENV highly corresponds to dengue hemorrhagic fever and dengue shock syndrome, which are the leading causes of high mortality. Due to lack of effective vaccines and unavailable therapies against DENV, discovery of anti-DENV agents is urgently needed. We first characterize that Schisandrin A can inhibit the replication of four serotypes of DENV in a concentration- and time-dependent manner, with an effective half-maximal effective concentration 50% (EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.